Nurix Therapeutics, Inc. NRIX Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s cumulative cost basis?
- Nurix Therapeutics, Inc. (NRIX) reported cumulative cost basis of $61.42M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s cumulative cost basis changed year-over-year?
- Nurix Therapeutics, Inc.'s cumulative cost basis increased by 11.2% year-over-year, from $55.21M to $61.42M.
- What is the long-term trend for Nurix Therapeutics, Inc.'s cumulative cost basis?
- Over 3 years (2022 to 2025), Nurix Therapeutics, Inc.'s cumulative cost basis has grown at a 17.8% compound annual growth rate (CAGR), from $36.83M to $60.27M.